Sociedad Americana de Hirudoterapia

Interaction of hementin with fibrinogen and fibrin

Biochemistry review published in Blood Coagul Fibrinolysis (1991)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewFarmacología salivalBudzynski AZ · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1991

Abstract

The giant Amazon leech Haementeria ghilianii manufactures blood anticoagulant which is present in the posterior and anterior salivary glands. The mechanism of blood anticoagulation by Haementeria ghilianii is completely different from that used by Hirudo medicinalis. The anticoagulant is mostly associated with a fibrinogen-degrading proteinase, hementin. However, other inhibitors of blood coagulation are also present in the salivary glands. The salivary gland extract inhibits platelet aggregation that is mostly attributable to the degradation of fibrinogen. Hementin purified by various methods has a molecular weight in the range of 80,000-120,000 and appears to be a metalloproteinase that is regulated by calcium ions. The enzyme degrades both fibrinogen and fibrin. The Michaelis constant for human fibrinogen is 1 microM. The cleavage of the isolated chains of fibrinogen is inefficient implying that the native conformation of the substrate may play a role in the recognition mechanism. The pattern of fibrinogen degradation by hementin resembles that caused by plasmin since products analogous to fragments Y, D and E are generated. However, the unique action of hementin on fibrinogen is in the initial proteolytic attack in the coiled-coil connector region while proteolysis of the alpha-chain is very slow. In consequence, unique fibrinogen fragments are formed that contain the entire COOH-terminus of the alpha-chain. The mechanism of blood anticoagulation by hementin is very efficient since the cleavage of only three peptide bonds in the fibrinogen molecule disassembles its bivalent structure and renders it non-functional.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, P.H.S.Review
Indexed MeSH termsAnimalsAnticoagulantsBlood CoagulationCalciumFibrinFibrinogenHumansLeechesMetalloendopeptidases

Resumen

Hementin, an 80–120 kDa calcium-dependent metalloproteinase from Haementeria ghilianii salivary glands, degrades fibrinogen and fibrin via unique cleavage in the coiled-coil connector region — a mechanism distinct from both hirudin (Hirudo) and plasmin.

Por qué esto importa para la hirudoterapia

The abstract characterises hementin, a fibrinogen-degrading metalloproteinase (molecular weight 80,000–120,000) produced in the salivary glands of the giant Amazon leech Haementeria ghilianii, whose anticoagulant mechanism differs entirely from that of Hirudo medicinalis. It reports hementin's calcium-regulated proteolytic activity on both fibrinogen and fibrin (Km for human fibrinogen of 1 µM), its initial attack on the coiled-coil connector region of fibrinogen, and the generation of unique fragments retaining the alpha-chain COOH-terminus, with cleavage of only three peptide bonds rendering fibrinogen non-functional. For ASH, this is directly relevant to understanding the molecular diversity of leech-derived anticoagulants. The abstract presents biochemical characterisation data; no clinical or in-vivo therapeutic claims are made.

Citación

Interaction of hementin with fibrinogen and fibrin.

Budzynski AZ · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1991

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.